The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.
IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.
Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.